Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Debt and Interest (Tables)

Debt and Interest (Tables)

3 Months Ended

Mar. 31, 2024

Debt and Interest

Schedule of Debt

Total debt consists of the following:


		March 31,			December 31,
($ in thousands)		2024			2023			Interest rate		Maturity

Oaktree Note		$	50,000		$	50,000		11.0	%	August - 2025
SWK Term Loan			15,000			15,000		15.1	%	December - 2027
Less: Discount on notes payable			(3,580)			(4,144)
Total notes payable		$	61,420		$	60,856

Interest Expense for all Debt Arrangements


		Three Months Ended March 31,
		2024									2023
($ in thousands)		Interest			Fees			Total			Interest			Fees			Total
Oaktree Note			1,390			502			1,892			1,390			424			1,814
Partner company convertible preferred shares			113			45			158			260			60			320
Partner company installment payments - licenses			—			—			—			91			—			91
Partner company notes payable			486			62			548			1,500			160			1,660
Other			4			—			4			79			332			411
Total Interest Expense and Financing Fee		$	1,993		$	609		$	2,602		$	3,320		$	976		$	4,296